Lexaria Bioscience Corp. Warrant - LEXXW STOCK NEWS

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced the granting of its 27th international patent in Mexico under registration #390001. This patent is part of Lexaria's third patent family, covering Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents, which has also received recognition in Australia, India, and Japan. The patent allows the use of DehydraTECH-processed non-psychoactive cannabinoids to treat various disorders, including hypertension and neurological diseases. Lexaria continues its regulatory pursuit for DehydraTECH-CBD in pharmaceutical applications.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) recently provided insights on third-party valuation methods for biotech firms. Highlighting the lengthy and costly drug development process, the company noted that its DehydraTECH-CBD program is advancing through FDA's clinical research phase. Valuation metrics show significant potential for drugs in different clinical trial phases, with estimated valuations of $88 million, $248 million, and $1.12 billion at the start of Phase I, II, and III, respectively. Lexaria indicated that pursuing the FDA's 505(b)(2) regulatory pathway could enhance approval prospects.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful completion of dosing in its clinical hypertension study, HYPER-H21-4, involving 64 patients. The study was randomized, double-blind, and placebo-controlled, aimed at assessing the safety and efficacy of DehydraTECH-CBD. Notably, no serious adverse events were reported, marking a significant safety milestone. The findings are anticipated to support an IND application to the FDA for further clinical testing. Secondary outcomes will include various cardiovascular health metrics, brain function, and overall health assessments, with data analyses expected to begin in September.

Lexaria Bioscience Corp. has issued a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals for the European, Australian, and New Zealand markets. The license allows AnodGen to manufacture and distribute cannabinoid active pharmaceutical ingredient powders and mandates royalty payments to Lexaria for all sales. This partnership aims to enhance bioavailability and absorption of cannabinoid products. AnodGen plans to operationalize its facility in Ireland by the end of 2022, aiming for significant growth in the pharmaceutical sector.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has filed a pre-Investigational New Drug (IND) meeting request with the FDA, successfully initiating communication regarding its DehydraTECH-CBD for hypertension treatment. The FDA confirmed receipt and set a target date of July 30, 2022 for follow-up, contingent on meeting specific conditions. This meeting aims to clarify Lexaria's IND-enabling development program ahead of a full IND application expected later in 2022 or early 2023. The hypertension market, valued at $28 billion, presents significant potential for Lexaria's innovative drug delivery technology.

Lexaria Bioscience Corp. (LEXXW, LEXX) has entered into a significant licensing agreement with Premier Wellness Science Co., Ltd. to utilize its DehydraTECH technology in the Japanese non-pharmaceutical market. Premier will make minimum payments of US$4,527,500 over five years to retain exclusivity, along with receiving royalty revenue from product sales. This partnership aims to address the booming Japanese CBD market, projected to exceed US$35 billion annually. Premier's parent company reported US$187 million in revenue for the first three quarters of 2021, signaling robust market potential.

Lexaria Bioscience Corp. announced the licensing of its DehydraTECH technology to Valcon Medical A/S, a European contract manufacturing organization. This license targets medical cannabis applications in the EU and UK. Lexaria is set to receive milestone fees and royalties from product sales, optimizing revenue potential as Valcon manufactures various cannabis products. Valcon's GMP certification enhances their credibility in the market. This collaboration aims to capitalize on the growing demand for effective medical cannabis solutions.

Lexaria Bioscience Corp. held its 2022 Annual Meeting on May 31, with 49.2% of shares represented. Key voting results included:

• Chris Bunka elected with 97.15% approval
• John Docherty elected with 87.25% approval
• Nicholas Baxter elected with 84.5% approval
• Ted McKechnie elected with 96.1% approval
• Albert Reese Jr. elected with 96.56% approval
• Davidson & Company LLP appointed as auditors with 98.77% approval
• Non-binding compensation approval for executives at 93.52%
• Directors' past actions ratified at 91.1%

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the receipt of its 25th patent for its DehydraTECH technology, specifically aimed at enhancing the delivery of antiviral drugs. The patent, No. 11,311,559, will be issued on April 26, 2022, validating the effectiveness of DehydraTECH in improving bioavailability. Studies show that antiviral drugs processed with this technology achieve peak blood concentrations double that of standard drugs. This patent reinforces Lexaria's commitment to innovation in drug delivery and enhances its patent portfolio across various countries.